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Nonphysiological overexpression of the ABC transporter P-
glycoprotein (P-gp), which is encoded by MDR1, has been
associated with reduced susceptibility to human immuno-
deficiency virus (HIV) type 1 infection in vitro. We analyzed
(1) the expression and genotype of MDR1 and their rela-
tionship to HIV-1 permissiveness of CD4+ T cells from 128
healthy blood donors and (2) the role that alleles of MDR1
exons 21 and 26 play in modifying disease progression in
411 HIV-1–infected individuals. Differences in physiological
levels of MDR1 expression did not modify HIV-1 infection
in vitro, nor did MDR1 alleles and haplotypes significantly
influence either permissiveness to infection in vitro or dis-
ease progression in vivo before the initiation of treatment.
The MDR1 gene codes for the ABC transporter P-glycoprotein
(P-gp). Protease inhibitors are substrates (as well as inhibitors
and/or inducers) of this transporter. The identification of poly-
morphisms in the MDR1 gene that are associated with changes
in transport function spurred much research, including that in
the field of HIV infection. The current state of knowledge has
been reviewed recently by Kim [1]. In addition to the interest
in the significance of P-gp in HIV therapeutics, there have been
3 reports on the potential role of P-gp in modulating cell sus-
ceptibility to HIV infection, independent of its role in drug
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transport [2–4]. These reports demonstrated a 50–70-fold de-
crease in viral production in cells overexpressing P-gp, effects
that were partially reversed by selective inhibition of the trans-
porter. The proposed mechanism includes the association be-
tween the transporter and glycolipid-enriched membrane do-
mains (lipid rafts) [5], important sites for viral fusion and
assembly and, thus, the disruption of HIV binding to the cell.
The experiments in the 3 reports cited were conducted in vitro
and used nonphysiological levels of P-gp expression in cell lines.
The reports pointed out that the possible role that P-gp plays in
modifying the natural evolution of disease in vivo in patients
not receiving antiretroviral therapy should be assessed. We ad-
dressed this issue by investigating (1) whether variation in MDR1
expression of purified CD4+ T cells would correlate with differ-
ences in permissiveness to HIV infection under standardized
infection conditions in vitro and (2) whether MDR1 polymor-
phisms associated with differences in MDR1/P-gp expression
would influence the progression of HIV infection in vivo before
the initiation of antiretroviral treatment.
Subjects, materials, and methods. Four hundred eleven
participants were recruited from within the genetics project of
the Swiss HIV Cohort Study (http://www.shcs.ch). The ethics
committees of all participant centers approved the study. Pa-
tients gave written, informed consent for genetic testing.
We established a collection of purified CD4+ T cells from
128 white, healthy blood donors, and the T cells were isolated
from peripheral blood mononuclear cells (PBMCs) by use of
anti-CD4+ magnetic beads (Miltenyi Biotech). Cells were cul-
tured in RPMI 1640 (GIBCO-Invitrogen) with 20% fetal calf
serum and 20 U of human IL-2/mL, at 37C and in 5% CO2.
The cells were characterized with respect to their permissive-
ness to HIV-1 infection in vitro under standardized conditions.
CD4+ T cells ( ) were infected with the R5 strain NL4-51.5  10
3BaL env (500 pg of p24). Both 5 and 7 days after infection,
p24 was measured in the culture supernatant by ELISA (Ab-
bott). Stocks of DNA and RNA were prepared to allow for
genetic testing.
Cells from donors and DNA from patients were genotyped at
MDR1 exons 21 (G2677T) and 26 (C3435T) by TaqMan allelic-
discrimination techniques (Applied Biosystems). For exon 21,
the primers were 5′-GGACAAGCACTGAAAGATAAGAAAGA-
3′ (forward) and 5′-TGAGGAATGGTTATAAACACATTCTT-
AGA-3′ (reverse), and the probes were 5′-ACCTTCCCAGcAC-
CTT-3′ (FAM) and 5′-CTTCCCAGaACCTT-3′ (VIC). For exon
26, the primers were 5′-TGCTGAGAACATTGCCTATGGA-3′
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Figure 1. MDR1 expression in CD4+ T cells, permissiveness to HIV-1 infection, and MDR1 alleles. No association was observed between MDR1
expression and permissiveness in CD4+ T cells from healthy blood donors (A). For the various alleles and haplotypes (B–D), an ordered trend (CC 1 CT 1
TT) was observed only for an association between the exon 26 genotypes at position 3435 and mRNA expression (C). The polymorphisms at MDR1 exons
21 (G2677T) and 26 (C3435T) were analyzed both separately and as composite genotypes: H1 p 2677GG and 3435CC (wild type); H2 p 2677GT or TT
and 3435CT or TT (2677T/3435T haplotype carrier); H3 p 2677GG and 3435CT or TT; and H4 p 2677GT or TT and 3435CC. The dotted line represents
the regression line; solid lines represent the mean.
and the probes were 5′-AAGAGATcGTGAGGGC-3′ (FAM) and
5′-AAGAGATtGTGAGGGCA-3′ (VIC). Data were also analyzed
with respect to the presence of the MDR1*2 haplotype (2677T/
3435T). Total RNA was extracted by use of an RNeasy MiniKit
(Qiagen), from viable PBMCs conserved in liquid nitrogen, and
was quantified by measurement of its optical density. The quan-
tification of MDR1 transcripts was performed by real-time poly-
merase chain reaction with primers designed to avoid am-
plification of genomic DNA; the primers were 5′-TGCTGA-
GAACATTGCCTATGGA-3′ (forward) and 5′-CCTTTGTCTCCT-
ACTTTAGTGCTATATTTATTAG-3′ (reverse), and the probe was
5′-CCTGTGACACCACCCGGCTGTTGT-3′ (VIC/TAMRA). Re-
sults for the target gene were normalized to b-actin RNA lev-
els by use of primers 5′-GATGACCCAGATCATGTTTGAGA-3′
(forward) and 5′-CACCGGAGTCCATCACGAT-3′ (reverse) and
probe 5′-CCTGTACGCCTCTGGCCGTACCAC-3′ (VIC/TAMRA).
Transcript levels were expressed in arbitrary units, calculated
by dividing the normalized amplification threshold cycle by the
score of a predefined sample.
Patients in whom 2 measurements of CD4+ T cells were
made before exposure to antiretroviral drugs and who were
successfully genotyped for MDR1 exons 21 (G2677T) and 26
(C3435T) were included in the analysis of in vivo progression
of HIV. The trajectory of CD4+ T cell depletion in each patient
was based on a repeat-measures random-effects model, by use
of MLwiN software. Log10 CD4
+ was modeled as a linear func-
tion of time and polymorphism group, with additional terms
for sex, age range (16–29 years, 30–39 years, 40–49 years, or
50 years), ethnicity (white or other), and risk group (injection
drug use or non–injection drug use). Both the intercept and
gradient of the trajectory of CD4+ T cells were allowed to vary
between patients. The average time for CD4+ T cells to decline
from 500 to 200 cells/mL was estimated for each polymorphism
group. The polymorphisms of MDR1 exons 21 (G2677T) and
26 (C3435T) were analyzed both separately and in combination
as composite genotypes: H1 p 2677GG and 3435CC (wild type);
H2 p 2677GT or TT and 3435CT or TT (2677T/3435T hap-
lotype carrier); H3 p 2677GG and 3435CT or TT; and H4 p
2677GT or TT 3435CC.
Results. The quantification of MDR1 transcripts in CD4+
T cells of healthy blood donors revealed that the mean  SD
interindividual variation in MDR1 expression was .2.04  1.73
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Figure 2. MDR1 allelic variants and HIV-1 infection. A, Influence on CD4+ T cells’ permissiveness to HIV-1 infection in vitro. Cells of 128 healthy blood
donors are analyzed. B, Influence of MDR1 allelic variants on disease progression in vivo. The dotted line represents the average time necessary for CD4+
T cells to decline. The trajectory of CD4+ T cells in 411 HIV-1–infected patients was based on a repeat-measures random-effects model adjusted for sex,
age group, ethnicity, and risk group. The polymorphisms at MDR1 exons 21 and 26 were analyzed separately and as composite genotypes, H1 to H4.
Lines represent the mean.
No correlation between MDR1 expression and permissiveness
to HIV-1 infection was observed (figure 1A). To determine
whether polymorphisms in MDR1 are associated with variation
in MDR1 expression in CD4+ T cells, genotyping was performed
at exon 21 (G2677T) and exon 26 (C3435T). The mean  SD
n-fold MDR1 expression was in cells with 2677GG,2.17  1.56
in cells with 2677GT, and in cells with1.97  1.64 2.05  2.10
2677TT ( ; figure 1B). An ordered trend (CC 1 CT 1P p .44
TT) was observed for an association between the exon 26 ge-
notypes at position 3435 and mRNA expression—2.34 
for 3435CC, for 3435CT, and for1.67 2.03  1.66 1.89  1.89
3435TT ( ; figure 1C)—and for H1 composite genotypesP p .19
versus non-H1 composite genotypes ( ; figure 1D). Analy-P p .09
sis of strict haplotypes (i.e., GG/CC vs. TT/TT vs. GG/TT vs.
TT/CC) did not alter the results.
Specific genotypes did not lead to measurable differences in
cell permissiveness to HIV infection in the in vitro system (figure
2A). Mean  SD p24 values (ng/mL) 7 days after infection were
for 2677GG, for 2677GT, and97.2  69.7 92.0  60.4 87.1 
for 2677TT ( ); the corresponding figures were54.2 P p .92
for 3435CC, for 3435CT, and93.1  73.8 89.0  56.1 94.5 
for 3435TT ( ). The results were similar after adjust-60.8 P p .89
ment for CCR5D32, CCR5 promoter polymorphism G59029A,
and CCR2 64I in multivariate analysis (data not shown). The
power was sufficient to detect 2-fold differences, in in vitro p24
levels, between the opposing homozygous groups (i.e., 2677GG
vs. TT and 3435CC vs. TT); a sample size of 1000 blood
donors would have been necessary to statistically corroborate
a 10% difference between these groups.
The influence of MDR1 allelic variants on disease progression
in vivo was analyzed by genotyping HIV-1–infected patients
unexposed to potent antiretroviral therapy. For the 411 patients
included in the analysis, the distribution of the MDR1 exon 21
(G2677T) polymorphism was 35% GG, 46% GT, and 19% TT;
for the MDR1 exon 26 (C3435T) polymorphism, the distribu-
tion was 24% CC, 49% CT, and 27% TT. The average time for
CD4+ T cells to decline from 500 to 200 cells/mL was 3.68 years
(95% confidence interval [CI], 3.09–4.56). For each genotype
and haplotype, the estimated time and 95% CIs for the decline
in CD4+ T cells is shown in figure 2B. At MDR1 exon 21, GG
homozygocity was associated with a slightly steeper decline in
CD4+ T cells (3.5 years [95% CI, 2.85–4.56]), compared with
TT (3.76 years [95% CI, 2.90–5.33]), whereas, at MDR1 exon
26, CC was associated with a somewhat less-steep decline (3.79
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years [95% CI, 2.96–5.28]) compared with TT (3.52 years [95%
CI, 2.83–4.66]). Analysis of composite genotypes showed a trend
toward faster decline in CD4+ T cells from H1 to H4 (H1 at 3.91
years [95% CI, 3.00–5.60] compared with H4 at 2.94 years [95%
CI, 1.83–7.36]); however, none of these differences reached con-
ventional levels of statistical significance.
Discussion. We observed 2- to 3-fold differences in MDR1
expression in CD4+ T cells from different individuals. This
variation in physiological levels of MDR1 expression did not
appear to contribute to CD4+ T cells’ susceptibility to HIV-1
infection in vitro. However, the results do not negate the re-
ports, by 3 independent research groups [2–4], of the effect of
P-gp overexpression in vitro in cell lines, and they do not exclude
effects that would have been uncovered by specific analysis of
P-gp expression in vivo. Cells overexpressing P-gp, such as the
L-MDR1 cell line [6], have an estimated 1000-fold-greater level
of MDR1 transcripts than do PBMCs.
MDR1 mRNA expression in purified CD4+ T cells correlated
with exon MDR1 polymorphisms in the present study—al-
though differences were not statistically significant—and with
the expression of both MDR1 and surface P-gp in PBMCs from
HIV-1–infected individuals that has been reported in our pre-
vious study [7]. Although there is controversy regarding the
biological relevance of MDR1 polymorphisms, most published
reports agree that there is an association between specific ge-
notypes or haplotypes and the above-mentioned observed dif-
ferences in either MDR1 expression or P-gp function [1]. The
reasons for this controversy are multiple, including that published
reports on genotype/phenotype relationships have used various
cell types (6 different cell sources), various ethnic origins for
study participants (3 ethnic groups), and different probe (i.e.,
test) drugs (digoxin, fexofenadine, cyclosporine, tacrolimus, nel-
finavir, rhodamine 123, and nortriptyline) [8] in analysis. In the
present study, we used MDR1 allelic variation as a surrogate for
MDR1 expression in vivo, and we assumed that transcript levels
reflect protein expression at the membrane; this was because in
our previous study we had shown, for the same set of samples,
a good correlation between transcript and protein expression [7].
Ifergan et al. investigated, in 137 white individuals heavily
exposed to HIV-1, whether MDR1 variants are associated with
risk of infection and concluded that the various alleles had no
relevant influence [9]. Our present work suggests that the phys-
iological differences in MDR1 expression do not appear to have
an influence on HIV-1 infection in the in vitro system used
and that MDR1 genotypes do not appear to modify disease
progression in vivo in a cohort of HIV-1–infected individuals.
Inclusion in the composite genotype/haplotype analysis of the
linked allele in exon 12 (C1236T) should not alter our overall
results and conclusion; however, we acknowledge that in vivo
the 95% CIs of the estimated time for CD4+ counts to decline
are wide and that therefore our study cannot, with certainty,
exclude a clinically relevant but small influence of MDR1/P-gp
expression and polymorphisms on HIV-1 disease evolution be-
fore the initiation of treatment.
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